Cerebral Folate Deficiency

FDA approves generic drug for a rare genetic condition

FDA approves leucovorin to treat rare cerebral folate deficiency

The Food and Drug Administration has approved expanded use of leucovorin calcium tablets for treating cerebral folate deficiency, a rare disorder.

· 2d

FDA approves generic drug for a rare genetic condition, but not for autism

· 2d · on MSN

FDA approves new use of synthetic vitamin B9 — but not for autism symptoms

· 2d

US FDA approves leucovorin for rare genetic disorder causing autism-like symptoms

WASHINGTON, March 10 (Reuters) - The U.S. FDA approved leucovorin, a decades-old generic drug, to treat a rare genetic disorder which causes autism-like symptoms on Tuesday, but not for children with...

· 1d

FDA won’t endorse Leucovorin for autism

· 1d

FDA OKs drug for rare brain disorder

GlobalData on MSN

FDA approves GSK’s Wellcovorin for cerebral folate deficiency

FDA worked with GSK to update Wellcovorin labelling for safe, effective use in adult and paediatric CFD-FOLR1 patients.

Fierce Pharma

FDA approves leucovorin for ultrarare cerebral folate deficiency subset without clinical trial

About five months after U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. | About five months after U.S. Health Secretary Robert F. Kennedy Jr. touted leucovorin as “an exciting therapy that may benefit large numbers of children who suffer from autism” during a White House press conference,

Medical Dialogues

FDA Approves First Treatment for Patients with Cerebral Folate Transport Deficiency

The U.S. Food and Drug Administration has approved expanded use of Wellcovorin (leucovorin calcium) tablets for the treatment of cerebral folate deficiency in adult and pediatric patients who

2don MSN

FDA approves leucovorin for rare genetic condition, but not for autism

The prescription drug leucovorin is getting a label update, though it’s not what that the US Food and Drug Administration suggested might be coming during a White House briefing in September, when officials touted the drug as a potential treatment for thousands of children with autism.